Allon Therapeutics Inc.

Allon Therapeutics Inc.

June 09, 2009 08:00 ET

Allon CEO to Present at Noble Financial Investment Conference

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 9, 2009) - Allon Therapeutics Inc. (TSX:NPC) has announced that President and CEO Gordon McCauley will present the Company's progress on its 2009 corporate and clinical milestones this morning at 8:40 a.m. EDT at Noble Financial Group's Fifth Annual Emerging Equity Conference in Hollywood, Florida.

The theme of McCauley's presentation is that the Company's existing cash resources are sufficient to fund its business into 2011 and meet its 2009 milestones.

The Allon presentation is being webcast live at:

In addition, presentations will be immediately archived and available for viewing for three months after the live webcast.

Noble Financial is a privately-held, full-service capital markets firm with a focus on emerging growth companies and with offices in New York, Boston, St. Louis and Boca Raton, FL.

About Allon

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon's drug davunetide intranasal (AL-108) has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer's disease. Allon has Phase II human efficacy programs pursuing large underserved markets: Alzheimer's disease, frontotemporal dementia, and schizophrenia-related cognitive impairment. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuro Protection Company™) and based in Vancouver. For additional information please visit the Company's website:

Forward Looking Statements

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, Allon's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and Allon's dependence on collaborative partners and contract research organizations. These factors can be reviewed in Allon's public filings at and should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements and Allon disclaims any obligation to update or announce changes in any such factors except in its periodic filings.

Contact Information